Beam Therapeutics Advances Phase 1/2 Trial for AAT Deficiency with Gene-Editing Therapy

Beam Therapeutics initiated a Phase 1/2 clinical trial for Alpha-1 Antitrypsin (AAT) deficiency using a one-time gene-editing AATD therapy, BEAM-302. The development aims to provide an accelerated FDA review path. The company presented trial data at the American Thoracic Society (ATS) conference.

BEAM has advanced BEAM-302, its one-time base-editing therapy for alpha-1 antitrypsin (AAT) deficiency, into a Phase 1/2 clinical trial, with early data presented at the American Thoracic Society (ATS) conference. AATD is a rare genetic disorder affecting an estimated 100,000 Americans, with no approved disease-modifying therapy.

The program is one of Beam's lead candidates and a key test of whether in vivo base editing can deliver durable, single-administration treatments outside of ex vivo blood disorders. Management has flagged a possible accelerated FDA review path given the unmet need and the magnitude of biomarker change expected from editing the underlying SERPINA1 mutation.

For investors, BEAM-302 is the most clinically de-risking catalyst of 2026 for the company. Watch ALT-protein levels, safety in the dose-escalation cohorts, and any commentary on commercial pricing assumptions or partnership economics as the trial reads out.

Related Stocks

BEAM